This unique award provides funding and committed project support by a team of pharmaceutical industry experts through a collaboration with the Alzheimer’s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute.
The 2021 ADDF-Harrington Scholar RFP places high priority on targets related to emerging therapeutic areas for dementia, particularly epigenetics and proteostasis. Other novel targets are encouraged, such as neurovascular health, neuroprotection, synaptic activity and neurotransmitters, inflammation, mitochondria and metaboloic function, ApoE, other aging targets. NOTE: This RFP does not support anti-amyloid approaches (e.g. Abeta vaccines, beta- or gamma-secretase inhibitors) or cholinesterase inhibitors.